1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is a progressive neurodegenerative disorder. Pathologically, AD is characterized by extracellular aggregation of amyloid-beta into senile plaques and hyper-phosphorylated tau protein accumulation in intraneuronal neurofibrillary tangles ([@bb0045]). Clinically, AD is characterized by progressive cognitive decline that typically presents with memory loss as the initial and primary concern ([@bb0025]). Worldwide, approximately 47.5 million individuals are living with dementia, the majority of which suffer from Alzheimer\'s disease ([@bb0260]).

Emerging research has focused on the identification of biomarkers that will assist with early diagnosis of AD and allow for the evaluation of potential disease modifying treatments ([@bb0085]). Considerable effort has been devoted to the development of PET molecular neuroimaging biomarkers of amyloid and tau in AD (e.g. [@bb0255]), however, magnetic resonance imaging (MRI) continues to offer a non-invasive and easily repeatable method of examining neuropathological changes associated with AD. To date, the majority of MRI-based research in AD has focused on tissue loss in grey matter structures ([@bb0065]). These findings indicate widespread whole brain grey matter atrophy in individuals with AD, including enlarged ventricles and decreased hippocampal volume ([@bb0095], [@bb0110], [@bb0170], [@bb0245]). In terms of white matter changes, the Amyloid Cascade Hypothesis ([@bb0115]) suggests that axonal degeneration arises as a result of Wallerian degeneration. However, the close association of tau with both axonal integrity and with the cognitive symptoms of AD suggests that white matter changes may occur independently and perhaps prior to changes in grey matter. Furthermore, the retrogenesis model proposed by [@bb0040] hypothesizes that white matter degeneration in AD follows a reverse pattern to that observed in early myelination. These ideas lend support to the notion of white matter changes in AD as biomarkers that may be particularly helpful in earlier identification of AD (see [@bb0030] for a review).

One promising tool to detect early white matter alterations in the brain is diffusion tensor imaging (DTI; [@bb0015], [@bb0220]). Currently, fractional anisotropy (FA) and mean diffusivity (MD) are the most frequently reported DTI metrics ([@bb0030]). FA is a measure of the degree of directionality of water diffusion, thought to be driven by microstructure such as cellular boundaries and myelin ([@bb0015], [@bb0030], [@bb0220]), while MD is a measure of the mean water diffusion rate ([@bb0220]). These metrics can provide information regarding changes or differences in restriction to diffusion that may reflect myelination and axonal integrity. Specifically, decreases in FA and increases in MD are indicative of decreased myelination and loss of axons, as a consequence of neurodegeneration ([@bb0050], [@bb0120], [@bb0190]).

The majority of published AD research has used a cross sectional design and consistently revealed low FA and high MD in widespread white matter regions including the frontal, parietal, and temporal lobes (including hippocampal regions), as well as the corpus callosum and longitudinal association tracts ([@bb0005], [@bb0195], [@bb0230], [@bb0240]). Microstructural water diffusion changes are not unique to AD, however. In fact, some of these changes occur during the healthy aging process. For example, [@bb0060] examined DTI indices from young and older adults and found an age-related reduction in FA within a number of white matter structures. These findings are consistent with recent reviews that discuss degeneration of white matter tracts with age, which may result from cerebrovascular changes or other common underlying health conditions (e.g. [@bb0140]).

Recent studies that have utilized a longitudinal design to investigate microstructural changes in AD via DTI have revealed decreased FA in the uncinate fasciculus ([@bb0125]) as well as FA and MD changes in the fornix, corpus callosum, and inferior cingulum, over time in individuals with AD ([@bb0090], [@bb0160]).

The current study is the first to use the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database to investigate changes in diffusion tensor imaging (DTI) metrics over time. The ADNI database has collected and made available DTI data from individuals with AD and healthy controls at multiple sites across North America. The overarching aim of the current study was to determine if DTI, as a measure of microstructural white matter integrity, has potential as a biomarker of AD. The study had two specific objectives: 1) to examine within-group microstructural white matter changes in individuals with AD and healthy controls at baseline and year one; and 2) to evaluate between-group differences in individuals with AD and healthy controls at both time points. It was hypothesized that 1) individuals with AD would have decreased FA and increased MD across time and that 2) individuals with AD would have lower FA and higher MD as compared to healthy controls at both time points. A whole brain exploratory approach was taken to capture differences between groups in any region, however, it was predicted that medial temporal regions would be more greatly affected in AD, compared to healthy controls, given that this is one of the first affected regions in the progression of AD grey matter pathology ([@bb0055], [@bb0095], [@bb0110], [@bb0170], [@bb0245]).

2. Method and materials {#s0010}
=======================

All data were obtained from the Alzheimer\'s Disease Neuroimaging Initiative 2 (ADNI2) database (<http://adni.loni.usc.edu>). The ADNI, led by Principal Investigator Dr. Michael W. Weiner, was launched in 2003 with the goal of testing whether longitudinal brain imaging, biological markers, and neuropsychological assessment can be used together to measure the progression of AD. For more information, please see [www.adni-info.org](http://www.adni-info.org){#ir0020}.

2.1. Participants {#s0015}
-----------------

Full eligibility criteria for the ADNI are described in the ADNI2 procedures manual ([@bb0020]). Briefly, individuals with AD met NINCDS/ADRDA criteria for probable AD ([@bb0150]), demonstrated abnormal memory function on the Wechsler Memory Scale (WMS) II (≤ 8 for 16 years education and above), had a MMSE score between 20 and 26, and had a Clinical Dementia Rating of 0.5 (very mild) or 1.0 (mild). Healthy controls were required to be free of subjective memory concerns, to have a score within the normal range on the WMS Logical Memory II (≥ 9 for 16 years of education and above), have a MMSE score between 24 and 30, and a Clinical Dementia Rating of 0 (none).

Individuals from the ADNI database were included in the present study if data was available at both baseline and year one. Data were retrieved from 34 individuals with AD (mean age = 75.8 ± 7.6; 10 females; MMSE = 23.59 ± 1.74; Logical Memory II = 1.65 ± 1.94) and 33 healthy age-matched controls (mean age = 73.0 ± 6.6; 16 females; MMSE = 29.03 ± 1.26, Logical Memory II = 11.70 ± 2.84). There were no significant differences between the two groups with respect to age, gender, or education ([Table 1](#t0005){ref-type="table"}). The mean number of days from baseline to year one was not significantly different between groups (394 ± 25 for AD, and 403 ± 54 for healthy controls).

All ADNI participants provided informed written consent approved by each sites\' Institutional Review Board. Secondary data use for the current study was approved by the Human Research Ethics Board at the University of Victoria, in British Columbia, Canada.

2.2. Image acquisition {#s0020}
----------------------

MRI data were downloaded from the ADNI2 database. All participants underwent whole-brain MRI scans according to the ADNI protocol. Images were acquired from 3 T MRI scanners (GE Medical Systems) from seven North American sites. Axial diffusion weighted image data were acquired with a spin echo planar imaging sequence. Scan parameters are as follows: acquisition matrix = 256 × 256, voxel size = 1.4 × 1.4 × 2.7 mm^3^, flip angle = 90°, number of slices = 59. There were 46 images acquired for each scan: 41 diffusion-weighted images (b = 1000 s/mm^2^) and 5 non-diffusion-weighted images (b = 0 s/mm^2^). Repetition time varied across scanning sites, but was approximately 12,500 to 13,000 ms.

2.3. Data analysis {#s0025}
------------------

### 2.3.1. Image preprocessing {#s0030}

All data analyses were performed in Functional MRI of the Brain Software Library (FSL) version 5.0 (Analysis Group, FMRIB, Oxford, UK, <http://fsl.fmrib.ox.ac.uk>; [@bb0210]). Diffusion weighted images were corrected for eddy current distortions and head movement using Eddy Correct and non-brain tissue was removed using Brain Extraction Tool ([@bb0205]). Brain-extracted images were then visually inspected to confirm accurate results.

### 2.3.2. Image analysis {#s0035}

FA maps were created using DTIfit and input into Tract-Based Spatial Statistics (TBSS) to obtain a projection of all participants\' FA data onto a mean FA skeleton ([@bb0215]). First, all participants\' FA data were non-linearly aligned to a common space (FMRIB58_FA). Then, the mean FA image was created and thresholded (FA \> 0.2) to create the mean FA skeleton. Next, each participant\'s FA data was projected onto the thresholded mean FA skeleton. Voxelwise statistical analysis of the white matter skeleton was performed using Randomise, FSL\'s nonparametric permutation inference tool. Threshold free cluster enhancement was used to correct for multiple comparisons (*p* \< 0.05). TBSS was also performed for MD; non-linear registration estimated from the FA images was applied to MD data and each participant\'s MD image was projected onto the mean FA skeleton before applying voxelwise statistics.

### 2.3.3. Statistical comparisons {#s0040}

Within-group comparisons were made for individuals with AD from baseline to year one, and for healthy controls from baseline to year one. Additionally, between-group contrast comparisons were made between individuals with AD and healthy controls at both baseline and at year one. White matter regions were identified with Johns Hopkins University\'s white matter atlas available in FSL ([@bb0155], [@bb0250]).

3. Results {#s0045}
==========

3.1. Within-group microstructural white matter changes in individuals with AD and healthy controls at baseline and year one {#s0050}
---------------------------------------------------------------------------------------------------------------------------

The within-group FA analysis showed that individuals with AD had reductions in FA in multiple regions, including the hippocampal cingulum, at year one compared to baseline ([Table 2](#t0010){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}A). Healthy controls also had reduced FA in similar regions across time, but these alterations were less extensive (as is visible in [Fig. 1](#f0005){ref-type="fig"}), and did not include the hippocampal cingulum ([Fig. 1](#f0005){ref-type="fig"}B). There were no significant increases in FA at year one compared to baseline in either group.

The within-group MD analysis showed that individuals with AD also had increased MD in multiple regions including the hippocampal cingulum at year one compared to baseline ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}A). Healthy controls also had increased MD at year one compared to baseline, but once again, these alterations were less extensive than in AD, and did not include the hippocampal cingulum ([Fig. 2](#f0010){ref-type="fig"}B). There were no significant decreases in MD at year one compared to baseline in either group.

3.2. Between-group differences in individuals with AD and healthy controls at baseline and year one {#s0055}
---------------------------------------------------------------------------------------------------

At baseline, between-group TBSS revealed that individuals with AD had lower FA relative to healthy controls ([Table 3](#t0015){ref-type="table"}; [Fig. 3](#f0015){ref-type="fig"}A). At year one, individuals with AD also had lower FA relative to healthy controls, and these alterations appeared more widespread than at baseline ([Fig. 3](#f0015){ref-type="fig"}B).

The between-group TBSS also revealed that individuals with AD had higher MD relative to healthy controls at baseline ([Table 3](#t0015){ref-type="table"}; [Fig. 4](#f0020){ref-type="fig"}A). At year one, individuals with AD had higher MD relative to healthy controls in similar regions as baseline, but there were also patterns of higher MD in the hippocampal cingulum, not seen at baseline ([Fig. 4](#f0020){ref-type="fig"}B).

No regions demonstrated greater FA or lower MD in HC compared to AD for either time point.

4. Discussion {#s0060}
=============

The current study is the first to examine *longitudinal* white matter changes using DTI data from the ADNI2 cohort. DTI indices of FA and MD were focused on in the current study, given that these are the most commonly reported metrics and can be interpreted in the context of recent literature ([@bb0030]).

The primary objective of the current study was to examine longitudinal white matter changes in individuals with AD and healthy aging. Significant changes in FA and MD were observed both in individuals with AD as well as in healthy controls at one year follow up. As expected, individuals with AD demonstrated decreased FA and increased MD in widespread white matter tracts (see [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}), including the hippocampal cingulum at year one compared to their baseline assessment. While healthy controls also exhibited decreased FA and increased MD in widespread white matter tracts (see [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}), these changes were less extensive than those observed in AD participants. Furthermore, healthy controls did not demonstrate FA or MD changes in the hippocampal cingulum as were observed in those with AD. Thus, the relatively widespread changes in larger white matter tracts seen in healthy controls may reflect age-related health factors such as vascular risk factors and the accumulation of other co-morbid health conditions (e.g., [@bb0265]). However, changes in microstructural integrity for the hippocampal cingulum over short time intervals (i.e. one year) may more specifically reflect ongoing degenerative process due to AD.

The second objective of the current study was to investigate between-group differences in individuals with AD and healthy controls at both baseline and year one. As predicted, significant between-group differences in FA and MD were observed in multiple regions at both time points ([Table 3](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}), including regions of the medial temporal lobe (e.g., hippocampal cingulum). Such between-group white matter differences are in line with previous cross-sectional studies that have observed DTI alterations in the same regions (i.e. corpus callosum, superior or inferior longitudinal fasciculus; cingulate; cingulum; fornix; and uncinate fasciculus) when comparing individuals with AD to age-matched healthy controls ([@bb0010], [@bb0050], [@bb0075], [@bb0130], [@bb0135], [@bb0165], [@bb0185], [@bb0190], [@bb0200], [@bb0225], [@bb0235]). Lower FA and higher MD in AD relative to controls at each time point likely reflects the more extensive and pathological neurodegeneration observed in AD. In particular, lower FA and higher MD in the hippocampal region is consistent with the early pathological progression of AD ([@bb0055], [@bb0110]) as well as memory loss as an initial and primary concern ([@bb0025]).

Although there have been few longitudinal DTI studies on individuals with AD, our findings are largely consistent with those published to date ([@bb0090], [@bb0125], [@bb0160]), demonstrating that such findings may be generalizable across AD populations --- especially, given ADNI\'s multi-site collection. Furthermore, these findings are consistent with the pathological progression observed in AD. In particular, the observed decreases in FA and increases in MD likely reflect the progressive loss of the water diffusion-restricting barriers in white matter (e.g., decreased level of myelination, loss of axons) as a consequence of neurodegeneration ([@bb0050], [@bb0120], [@bb0190]). Currently, the mechanisms underlying white matter pathology in AD are not well understood. It is hypothesized that some damage to white matter may occur secondarily to grey matter pathology via Wallerian degeneration, but additional white matter alterations may also occur independent from grey matter pathology, as put forth by the retrogenesis hypothesis, for example ([@bb0030], [@bb0040]).

In summary, the current whole brain DTI study found evidence of a higher rate of decline in FA and increase in MD over approximately one year in individuals with AD versus matched healthy controls. These differential changes were seen in a number of white matter regions that correspond to regions know to be affected in AD. Importantly however, these DTI changes were evident in the hippocampal cingulum only in those with AD and not healthy controls, a finding that is consistent with the known pattern of progression of AD pathology in the grey matter of medial temporal regions ([@bb0055]). Volume reduction in the hippocampal grey matter is well documented in previous AD research ([@bb0110]). The current findings suggest there are microstructural alterations in hippocampal white matter as well. It is currently unknown whether microstructural changes can be detected earlier than volumetric changes. Thus, future work should focus on both hippocampal grey and white matter, given that the observed hippocampal changes appear specific to AD relative to aging.

A potential limitation of the current study concerns the criteria used to diagnose AD. There are varying definitions of AD, and the inclusion/exclusion criteria may differ across studies, making cross-study comparisons and generalizations to all individuals with AD challenging. Furthermore, there is heterogeneity in the ADNI AD sample; disease stage may not be equivalent in the baseline scans and there is no pathological verification of diagnosis for all members of the AD cohort.

White matter hyperintensities (WMH) of presumed vascular origin were not accounted for in the current analysis. This represents a potential limitation as WMH are common in older adults and have been shown to be related to lower FA and higher MD relative to normal appearing white matter (e.g., [@bb0145]). However, the ADNI database has previously been shown to have participants with lower levels WMH relative to other large-scale data sources ([@bb0180]). Future DTI studies in aging populations may consider including WMH to overcome this limitation.

Additionally, although the ADNI2 database includes neuroimaging data from individuals diagnosed with mild cognitive impairment (MCI), the current study did not examine this group, as the primary objective was to characterize white matter in AD, specifically. Approximately 10 to 15 percent of individuals with MCI progress to AD annually ([@bb0100]), in contrast to the 1 to 2 percent of healthy older adults who progress to AD per year ([@bb0175]). Thus, future studies of longitudinal DTI changes in those with MCI may be helpful in determining whether the DTI changes noted in our AD sample represent sensitive and specific neuroimaging biomarkers of AD pathophysiologic processes in individuals in the prodromal stages of this disease. It is important to recognize that MCI cannot be considered synonymous with early AD ([@bb0035]). As noted by [@bb0080], MCI applies to a heterogeneous group of aging adults with cognitive concerns, regardless of the underlying etiology or symptom progression. Future studies are likely to require relatively large and well-characterized study samples, longer follow up periods to adequately observe conversion from MCI to AD, as well as multimodal imaging protocols in order to adequately address this issue.

Data collection for ADNI2 is currently ongoing. As new data are added to the database, the current findings should provide support for additional analyses of DTI white matter changes to assist in the development of potential biomarkers of AD. Future studies that draw from the ADNI database will benefit from these multi-year longitudinal data (up to five years). Not only will the number of participants in each study group grow as additional participants are recruited, the trajectory of the disease progression can be better tracked across longer time periods as data collection with the current cohort continues.

5. Conclusion {#s0065}
=============

A major focus of research on AD centres on the investigation of biomarkers. To date, most studies have focused on changes in grey matter and taken a cross sectional approach. The current study is the first to examine *longitudinal* white matter changes using the ADNI2 cohort. The results revealed that changes in FA and MD occurred over a one year period in both patients with AD and healthy controls, although the changes were more extensive in AD and more specific to the medial temporal lobe. DTI holds potential as an AD biomarker though multi-year tracking of brain imaging and AD clinical signs at different diagnostic stages are needed to fully evaluate its clinical utility. Ultimately, better characterization of longitudinal microstructural white matter changes may lead to pre-symptomatic detection and better outcomes for individuals with AD.
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###### 

Participant demographics at baseline and year one.

Table 1

                  Baseline     Year one                                             
  --------------- ------------ ------------ ------------- ------------ ------------ -------------
  Age             75.8 ± 7.6   73.0 ± 6.6   *p* = 0.104   76.9 ± 7.7   74.1 ± 6.5   *p* = 0.114
  \# of males     24           17           *p* = 0.113   --           --           --
  \# of females   10           16                         --           --           --
  Education       15.7 ± 2.9   16.4 ± 2.8   *p* = 0.347   --           --           --

*t*-Tests used to obtain *p*-values.

###### 

Number and percentage of total significant voxels in regions with significantly (decreased) fractional anisotropy and/or (increased) mean diffusivity at year one compared to baseline in individuals with Alzheimer\'s disease and in healthy controls.

Table 2

  ---------------------------------------------------------------------------------------------------------
  White matter regions                        Alzheimer\'s disease   Healthy controls             
  ------------------------------------------- ---------------------- ------------------ --------- ---------
  Corpus callosum                             5842\                  5087\              3715\     3700\
                                              (77.3%)                (67.3%)            (49.2%)   (49.0%)

  Internal capsule                            2868\                  2247\              1769\     2368\
                                              (59.8%)                (46.8%)            (36.9%)   (49.4%)

  External capsule                            2195\                  1537\              1017\     1297\
                                              (70.7%)                (49.5%)            (32.8%)   (41.8%)

  Corona radiata                              3710\                  4538\              1794\     3079\
                                              (49.7%)                (60.7%)            (24.0%)   (41.2%)

  Posterior thalamic radiations               1809\                  1144\              1351\     996\
                                              (80.8%)                (51.1%)            (60.3%)   (44.5%)

  Longitudinal fasciculi                      1775\                  1453\              312\      953\
                                              (56.5%)                (46.2%)            (9.9%)    (30.3%)

  Fronto-occipital fasciculi                  3\                     3\                 3\        5\
                                              (30.0%)                (30.0%)            (30.0%)   (50.0%)

  Cingulum (white matter of cingulate gyri)   758\                   374\               239\      305\
                                              (77.4%)                (38.2%)            (24.4%)   (31.2%)

  Hippocampal cingulum                        272\                   218\               0\        0\
                                              (70.1%)                (49.0%)            (0.0%)    (0.0%)

  Fornix                                      393\                   243\               322\      333\
                                              (56.9%)                (35.2%)            (46.6%)   (48.2%)

  Corticospinal tract                         338\                   254\               290\      212\
                                              (54.7%)                (41.1%)            (46.9%)   (34.3%)

  Uncinate Fasciculus                         90\                    55\                30\       0\
                                              (75.0%)                (45.8%)            (25.0%)   (0.0%)

  Tapetum                                     38\                    36\                14\       9\
                                              (95.0%)                (90.0%)            (35.0%)   (47.5%)

  Medial lemniscus                            227\                   218\               157\      183\
                                              (55.4%)                (53.2%)            (38.3%)   (44.6%)

  Cerebellar peduncle                         2402\                  1837\              1834\     1381\
                                              (65.2%)                (49.9%)            (49.8%)   (37.5%)

  Cerebral peduncle                           873\                   496\               756\      647\
                                              (66.3%)                (37.7%)            (57.4%)   (49.1%)
  ---------------------------------------------------------------------------------------------------------

###### 

Number and percentage of total significant voxels in regions with low fractional anisotropy and high mean diffusivity in individuals with Alzheimer\'s disease (AD) compared to healthy controls (HC) at baseline and at year one.

Table 3

  --------------------------------------------------------------------------------------
  White matter regions                        Baseline   Year one             
  ------------------------------------------- ---------- ---------- --------- ----------
  Corpus callosum                             4378\      5076\      6306\     6327\
                                              (57.9%)    (67.2%)    (83.0%)   (83.3%)

  Internal capsule                            555\       1264\      1675\     1468\
                                              (11.6%)    (26.3%)    (34.8%)   (30.5%)

  External capsule                            845\       927\       1800\     1327\
                                              (27.2%)    (29.9%)    (58.1%)   (42.8%)

  Corona radiata                              2981\      5678\      3566\     6424\
                                              (39.9%)    (76.0%)    (48.1%)   (86.6%)

  Posterior thalamic radiation                1233\      1092\      1496\     1096\
                                              (55.1%)    (48.8%)    (66.4%)   (48.7%)

  Longitudinal fasciculi                      909\       1826\      1535\     2135\
                                              (28.9%)    (58.1%)    (48.7%)   (67.7%)

  Fronto-occipital fasciculi                  0\         2\         0\        4\
                                              (0.0%)     (20.0%)    (0.0%)    (40.0%)

  Cingulum (white matter of cingulate gyri)   597\       423\       856\      535\
                                              (61.0%)    (43.2%)    (90.4%)   (56.5%)

  Hippocampal cingulum                        351\       0\         142\      168\
                                              (90.5%)    (0.0%)     (35.3%)   (41.8%)

  Fornix                                      339\       297\       581\      356\
                                              (49.1%)    (43.0%)    (85.7%)   (52.5%)

  Corticospinal tract                         0\         0\         70\       0\
                                              (0.0%)     (0.0%)     (11.4%)   (0.0%)

  Uncinate fasciculus                         70\        43\        94\       69\
                                              (58.3%)    (35.8%)    (77.7%)   (57.0%)

  Tapetum                                     38\        39\        36\       37\
                                              (95.0%)    (97.5%)    (97.3%)   (100.0%)

  Medial lemniscus                            0\         0\         251\      0\
                                              (0.0%)     (0.0%)     (64.5%)   (0.0%)

  Cerebellar peduncle                         0\         0\         1662\     0\
                                              (0.0%)     (0.0%)     (47.1%)   (0.0%)

  Cerebral peduncle                           0\         9\         751\      3\
                                              (0.0%)     (0.7%)     (56.9%)   (0.2%)
  --------------------------------------------------------------------------------------

[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.
